Xtl Biopharmaceuticals (XTLB) Free Cash Flow Growth (1y) (2010 - 2016)
Xtl Biopharmaceuticals (XTLB) Free Cash Flow Growth (1y) (2010 - 2016) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.82 Bn | 1,785.76 Bn | - | - |
| 2 | Akari Therapeutics | 979.03 Bn | 979.03 Bn | - | - |
| 3 | BeOne Medicines | 473.13 Bn | 468.34 Bn | 1.35 Bn | 1,092.51% |
| 4 | Vertex Pharmaceuticals | 123.67 Bn | 116.43 Bn | 2.59 Bn | 66.37% |
| 5 | Regeneron Pharmaceuticals | 71.57 Bn | 62.81 Bn | 3.31 Bn | 3.98% |
| 6 | Belite Bio | 62.00 Bn | 62.00 Bn | - | - |
| 7 | Argenx Se | 54.61 Bn | 49.42 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 37.99 Bn | 34.98 Bn | 959.66 Mn | 137.65% |
| 9 | Revolution Medicines | 36.09 Bn | 36.09 Bn | - | - |
| 10 | Xtl Biopharmaceuticals | 2.47 Bn | 2.47 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 0.78% |
| Dec 31, 2015 | 663.46% |
| Sep 30, 2015 | 3.74% |
| Jun 30, 2015 | 5.19% |
| Dec 31, 2014 | -51.57% |
| Sep 30, 2014 | 39.97% |
| Jun 30, 2014 | 18.92% |
| Mar 31, 2014 | -45.14% |
| Dec 31, 2013 | -10.40% |
| Sep 30, 2013 | -61.28% |
| Jun 30, 2013 | -93.60% |
| Mar 31, 2013 | -93.26% |
| Dec 31, 2012 | -276.42% |
| Sep 30, 2012 | -91.06% |
| Jun 30, 2012 | -3.61% |
| Mar 31, 2012 | 29.50% |
| Dec 31, 2011 | 181.21% |
| Sep 30, 2011 | -17.70% |
| Jun 30, 2011 | -204.59% |
| Mar 31, 2011 | -196.30% |